Active substance

Results for the substance ledipasvir+sofosbuvir

1 result

About this active substance

The combination of ledipasvir and sofosbuvir is used to treat chronic hepatitis C. This is a direct-acting antiviral therapy that works by inhibiting the enzymes necessary for the replication of the hepatitis C virus (HCV).

The medication is taken orally, usually once daily, for a period of 8-12 weeks, depending on the virus genotype and disease stage. It is highly effective, with cure rates exceeding 90% in most cases.

Side effects may include fatigue, headaches, nausea, or insomnia. In rare cases, severe allergic reactions may occur.

Patients should inform their doctor about any other medications they are taking, as drug interactions may occur. Pregnant or breastfeeding women should consult a specialist before starting treatment.